Form 4: Raphael Pharmaceutical Inc. Executive Exercises Warrants for Common Stock
SEC Form 4 Filing
Igal Louria Hayon, Chief Technology Officer of Raphael Pharmaceutical Inc., exercised warrants to purchase 999,000 shares of common stock at $0.01 per share on August 29, 2023.
Summary
- On August 29, 2023, Igal Louria Hayon, the Chief Technology Officer of Raphael Pharmaceutical Inc., exercised warrants to acquire 999,000 shares of the company's common stock.
- The exercise price for the warrants was $0.01 per share.
- Following the transaction, Mr. Hayon directly owns 999,000 shares of Raphael Pharmaceutical Inc. common stock.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing, so the sentiment is considered neutral.
Industry Context
This is a standard disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.
Stakeholder Impact
- The exercise of warrants increases the number of outstanding shares, which could potentially dilute existing shareholders' ownership.
Key Dates
| Date | Description |
|---|---|
| 12/05/2022 | Date warrants were exercisable |
| 08/29/2023 | Date of warrant exercise |
| 07/05/2024 | Expiration date of warrants |
| 03/25/2024 | Date of Form 4 filing |
Keywords
Form 4, Beneficial Ownership, Warrants, Common Stock, Executive, RAPH, Raphael Pharmaceutical Inc., Igal Louria Hayon
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.